Press releases

QuantomiX launches a revolutionary Lipid Imaging Service to advance studies of new treatments for diabetes, obesity and cardiovascular disease.

February 14, 2006, Rehovot, Israel - QuantomiX Ltd., a leading provider of unique diagnostic imaging modalities, has launched a new and first-of-its-kind Lipid Imaging Service. This revolutionary service is designed to advance preclinical and clinical studies of drug treatments for diabetes, obesity and cardiovascular disease. QuantomiX Lipid Imaging Service is unique in offering accurate high resolution imaging and quantification of lipid accumulation in tissues, blood samples and cultured cells. It has already successfully been used to evaluate samples from skeletal muscle, liver, adipose tissue, kidney, pancreas, and aorta.

QuantomiX service features WETSEM^TM technology, a unique, proprietary method for lipid imaging and quantification. The Lipid Imaging Service is expected to open new vistas in drug development for Metabolic Syndrome and other hitherto unexplored avenues of research.

Barbara Corkey, Ph.D., Professor of Medicine and Biochemistry and Director of the Obesity Research Center at Boston Medical Center, Boston University, is enthusiastic about the new service: "QuantomiX new service promises to be an important aid in lipid accumulation research, which is an integral part of medical research on obesity."

About QuantomiX

QuantomiX develops and markets breakthrough solutions based on its proprietary WETSEM™ technology. QuantomiX innovative technology, which allows high resolution imaging of wet samples, opens new opportunities for application-specific tools to improve drug discovery, and advances treatment and diagnostic solutions for the medical and pharmaceutical markets.